NASDAQ:AKTS Aktis Oncology Q3 2026 Earnings Date & Estimates $16.01 -0.48 (-2.91%) Closing price 04:00 PM EasternExtended Trading$16.02 +0.00 (+0.03%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Aktis Oncology is estimated to report Q3 2026 earnings on Thursday, November 12, 2026. The conference call is scheduled for November 13, 2026 at 4:00 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 12, 2026Conference Call DateNovember 13, 2026Conference Call4:00 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Aktis Oncology in Q3 2026Aktis Oncology is expected to post earnings of -$0.47 per share on revenue of $4.02 million. Aktis Oncology last reported on August 13, 2026, posting -$0.4370 per share and missing the -$0.4307 consensus estimate. Aktis Oncology has beaten the consensus EPS estimate in 1 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.47Expected Revenue$4.02 millionRecent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.4370 (Missed by -$0.0064)Last Quarter Revenue$3.38 millionEPS Beat Rate1 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Aktis Oncology Q3 2026 Earnings FAQ When does Aktis Oncology report Q3 2026 earnings? Aktis Oncology (NASDAQ:AKTS) is estimated to report Q3 2026 earnings on Thursday, November 12, 2026. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Aktis Oncology's Q3 2026 earnings call? Aktis Oncology's Q3 2026 earnings conference call is scheduled for Friday, November 13, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Aktis Oncology? Analysts expect Aktis Oncology to post earnings of -$0.47 per share for Q3 2026. How much revenue is Aktis Oncology expected to report? The consensus revenue estimate for Aktis Oncology is $4.02 million for Q3 2026. Aktis Oncology Earnings HeadlinesAktis Oncology: Padcev Is Building The Market It WantsOctober 14 at 4:31 PM | seekingalpha.comAktis Oncology, Inc. (AKTS)October 8, 2026 | finance.yahoo.comBuffett's Final Warning: "The Dollar Is Going to Hell"On May 3rd, 2025, Warren Buffett looked at his shareholders for the last time and said: "The dollar is going to hell." Ray Dalio agrees. The founder of Bridgewater Associates ($150 billion AUM) calls it a "debt death spiral." But there's a specific asset class and investment system that actually thrives when the dollar collapses.October 15 at 1:00 AM | Decentralized Masters (Ad)Wedbush Reaffirms Their Buy Rating on Aktis Oncology, Inc. (AKTS)October 7, 2026 | theglobeandmail.comOncocyte (NASDAQ:IMDX) & Aktis Oncology (NASDAQ:AKTS) Head-To-Head SurveyOctober 5, 2026 | americanbankingnews.comAktis Oncology (NASDAQ:AKTS) Earns "Outperform" Rating from WedbushOctober 4, 2026 | americanbankingnews.comSee More Aktis Oncology Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Aktis Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aktis Oncology and other key companies, straight to your email. Email Address About Aktis OncologyAktis Oncology (NASDAQ:AKTS), Inc. is a clinical-stage biopharmaceutical company developing targeted alpha therapies for the treatment of cancer. Its research is focused on creating therapies designed to selectively deliver alpha-particle radiation to tumor cells while limiting exposure to surrounding healthy tissue. The company’s platform uses proprietary tumor-targeting molecules, including engineered miniproteins, to bind specific targets found on cancer cells and transport radioactive payloads to tumors. Aktis Oncology is advancing a pipeline of investigational programs intended to address solid tumors and other cancers where targeted radiotherapy may offer a therapeutic benefit. As an early-stage biotechnology company, Aktis Oncology’s products remain in development and have not been broadly commercialized. Information about its clinical pipeline, corporate leadership, and geographic operations may change as the company progresses its research and development programs.View Aktis Oncology ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin PressureASML Can’t Keep Up With AI Demand—Why That's a Good ThingCiti Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenBig Banks Report Strong Earnings—So Why Are Shares Falling? Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
